© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions
Posted 18th February 2020

Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions

Top Blood and Marrow Transplant and Immunotherapy programs depend on Title21 Health Solution’s (Title21) technology to manage the patient, product and process data from collection to infusion. We had a chance to catch up with Lynn Fischer, the CEO at Title21 who provided us with a detailed insight into the award-winning software provider.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions
Title21

Top Blood and Marrow Transplant and Immunotherapy programs depend on Title21 Health Solution’s (Title21) technology to manage the patient, product and process data from collection to infusion. From reporting to analytics, Title21 provides all the critical data at your fingertips so the right person has the right data at the right time to make the right decisions. This allows Medical Technologists, Technical and Medical Directors to focus on higher-value work, and ultimately the patient, rather than chasing down paperwork and people.

Earlier this year, Title21 was selected as the Most Outstanding Cell Therapy Software Provider for 2019 by AI’s Global Excellence Award. We had a chance to catch up with Lynn Fischer, the CEO at Title21 who provided us with a detailed insight into the award-winning software provider.

Since their inception, Tile21’s Cloud and onpremise software manages critical patient, product and process data for cell and gene therapy, immunotherapy and regenerative medicine to ensure quality, compliance and traceability. Programs that implement Title21 solutions find they can scale more effectively to treat more patients and can also translate products more quickly and efficiently from bench to bedside, delivering the latest innovative therapies to patients faster and more safely.

Title21 has served FDA-regulated life science companies for many years with quality management software, so Title21’s experience has been of great service to the cell therapy segment. “Our technology is extremely flexible due to its configurability on the front end. That means that we can maintain a single code base while meeting each cancer center or cell manufacturers’ specific requirements.”

“Every team member at Title21 is dedicated to supporting the lifesaving work that health care providers do each and every day.”

“At Title21, we partner with the largest and top-rated cancer hospitals – placing the patient first. One of our greatest testimonials we hear often is that our customers want us to continue to solve more of their challenges with our technology. They ask Title21 to help provide solutions through technology to increase the quality, safety and efficiency of their programs.” Current Title21 customers have a strong influence on the technology roadmap to add value to patient therapeutic care and quality. Analytics and business intelligence are also important and play a significant role in the future of developing new cures and protocols more quickly and efficiently. Cell and gene therapy is a dynamic market and the protocols are changing rapidly as they are improved and refined.

Moving forward, the future looks bright for the team at Title21 as they continue to provide exceptional services and award-winning solutions to hospitals and biotech firms. “Our passion is to serve the many patients and their families who face life-threatening diseases by supporting the leading healthcare institutions and biotech companies with powerful tools that help them deliver innovative treatments to their patients. Every team member at Title21 is dedicated to supporting the lifesaving work that health care providers do each and every day” remarks Fischer.

Bringing the interview to a close, Lynn signs off by revealing the exciting plans which lie in the pipeline for the business, which includes their ambitions to further expand the business in the years to come, especially with the advancements in immunotherapy technology.

Categories: Innovation


You Might Also Like
Read Full PostRead - Eye Icon
Health Care M&A Spending Sets New Record in 2015
Innovation
24/11/2015Health Care M&A Spending Sets New Record in 2015

The health care merger and acquisition market has set a new record in 2015, with more than a month left to go to the end of the year.

Read Full PostRead - Eye Icon
6 Benefits of Outsourcing Managed IT Services
Strategy
02/03/20226 Benefits of Outsourcing Managed IT Services

Outsourcing may be one of the strategies to be considered by businesses to remain focused on the services and products they provide while keeping expenses down.

Read Full PostRead - Eye Icon
Best SaaS to Help Improve Your Services
Innovation
28/09/2021Best SaaS to Help Improve Your Services

The business landscape has changed dramatically in recent times, as technology is booming and has become central to businesses across all industries.

Read Full PostRead - Eye Icon
Unemployment Rate Still Masking a Recovery on the Rocks
Finance
26/05/2015Unemployment Rate Still Masking a Recovery on the Rocks

Modest growth in April jobs isn’t enough of a silver lining to hide a bad GDP report

Read Full PostRead - Eye Icon
Building a Scalable Women-Owned Business in Male-Dominated Industries
Strategy
08/06/2026Building a Scalable Women-Owned Business in Male-Dominated Industries

Building a women-owned business in a male-dominated industry requires resilience, strategic planning, and access to the right support systems. Although more women across the UK are launching businesses than ever before, barriers still exist. Gender bias, reduc

Read Full PostRead - Eye Icon
Why MBO Is the Best ESOP Advisor for Business Owners Seeking a Tax-Efficient Exit
Innovation
26/03/2026Why MBO Is the Best ESOP Advisor for Business Owners Seeking a Tax-Efficient Exit

At a certain point, most business owners stop asking what their company is worth and start asking what they will actually keep. That shift tends to happen quietly, often after years of growth, reinvestment, and building something that feels bigger than a balan

Read Full PostRead - Eye Icon
Local SEO Strategies for Service Providers: Ranking Higher in Searches
News
29/08/2023Local SEO Strategies for Service Providers: Ranking Higher in Searches

Local SEO is a linchpin for service providers striving to improve their online presence or to connect with their target audience effectively. Optimizing a website for local search can make all the difference in attracting nearby customers or clients. As an int

Read Full PostRead - Eye Icon
Fashion Startup: How to Market Your Brand and Acquire Customers
News
19/02/2024Fashion Startup: How to Market Your Brand and Acquire Customers

Starting a fashion brand in today’s competitive market requires more than just a keen eye for style. With countless emerging designers and established brands vying for attention, effective marketing strategies are essential for standing out and acquiring

Read Full PostRead - Eye Icon
Investcorp Expands Real Estate Portfolio with Acquisition of Four Residential Properties
Finance
25/03/2015Investcorp Expands Real Estate Portfolio with Acquisition of Four Residential Properties

Investcorp, a leading provider and manager of alternative investment products, today announced that its U.S.-based real estate arm, through separate transactions, has acquired a portfolio of residential properties in the metropolitan areas of Washington, D.C.,



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow